Actinium Pharmaceuticals (ATNM) Other Non-Current Liabilities (2012 - 2021)
Actinium Pharmaceuticals (ATNM) posted quarterly Other Non-Current Liabilities of $998000.0 for Q4 2021, up 6170.42% quarter-over-quarter from $15916.0 in Q4 2018.
Actinium Pharmaceuticals (ATNM) Other Non-Current Liabilities (2012 - 2021) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Other Non-Current Liabilities for 8 consecutive years, with $998000.0 the latest figure, recorded in Q4 2021.
- In Q4 2021, Other Non-Current Liabilities changed N/A year-over-year to $998000.0; the TTM figure through Dec 2021 stood at $998000.0 (changed N/A YoY), while the FY2021 annual figure was $998000.0, changed N/A from the prior year.
- Other Non-Current Liabilities improved to $998000.0 in Q4 2021 per ATNM's latest filing, from $15916.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $998000.0 in Q4 2021 and bottomed at -$15916.0 in Q3 2018.
- Historically, Other Non-Current Liabilities has averaged $260829.1 across 3 years, with a median of $35120.5 in 2017.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 0.0% in 2018 and fell as far as 129.3% in 2018.
- Actinium Pharmaceuticals' Other Non-Current Liabilities stood at $15916.0 in 2017, then changed by 0.0% to $15916.0 in 2018, then soared by 6170.42% to $998000.0 in 2021.
- Business Quant data shows ATNM's Other Non-Current Liabilities at $998000.0 in Q4 2021, $15916.0 in Q4 2018, and -$15916.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 998,000.00 |
| Dec 31, 2018 | 15,916.00 |
| Sep 30, 2018 | -15,916.00 |
| Jun 30, 2018 | 15,916.00 |
| Dec 31, 2017 | 15,916.00 |
| Sep 30, 2017 | 54,325.00 |
| Jun 30, 2017 | 426,442.00 |
| Mar 31, 2017 | 576,034.00 |
| Dec 31, 2016 | 300,683.00 |
| Sep 30, 2016 | 431,808.00 |
| Jun 30, 2016 | 934,586.00 |
| Mar 31, 2016 | 1.23 Mn |
| Dec 31, 2015 | 2.85 Mn |
| Sep 30, 2015 | 1.23 Mn |
| Jun 30, 2015 | 1.92 Mn |
| Mar 31, 2015 | 1.86 Mn |
| Dec 31, 2014 | 6.71 Mn |
| Sep 30, 2014 | 8.22 Mn |
| Jun 30, 2014 | 9.83 Mn |
| Mar 31, 2014 | 19.13 Mn |